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Objective: Autologous platelet clots serve as slow-release delivery systems for platelet-derived growth factors
and cytokines. Their application to the pericardial sac might facilitate salvage and repair of ischemically injured
myocardium. However, little is known about platelet clot stability in the pericardial sac. We investigated the sta-
bility of platelet clots in vitro and after administration to the pericardial sac in pigs and patients.
Methods: In 5 Yorkshire-Landrace pigs and 10 patients, in vitro manufactured autologous platelet gel (Medtronic
Magellan Platelet Separator) and platelet-rich fibrin (Vivolution Vivostat System) were administered to the peri-
cardial sac for 30 minutes. Two antifibrinolytics (tranexamic acid and aprotinin) were tested for their capacity to
stabilize autologous platelet gel. In vitro clots, incubated at 37C for 48 hours, served as controls. Clot weight was
measured before and after administration.
Results: In vitro, autologous platelet gel clots of either formula liquefied almost entirely within 60 minutes
whereas platelet-rich fibrin clots remained intact. In the pig, platelet clot weight decreased to 16.7%  7.8%
(P< .05) and 66.4%  3.2% (P< .05) of initial clot weight for autologous platelet gel and platelet-rich fibrin,
respectively. Addition of antifibrinolytics to autologous platelet gel did not reduce clot degradation significantly.
In patients, autologous platelet gel and platelet-rich fibrin clot weight remained 9.0%  1.5% (P< .05) and
73.7%  2.6% (P< .05) of initial clot weight, respectively.
Conclusions: Autologous platelet gel is unstable both in vitro and in vivo, whereas platelet-rich fibrin remains
intact in vitro and, compared with autologous platelet gel, is less subject to degradation in pigs and in patients.
General Thoracic Surgery Rademakers et alThe pericardium serves as a biochemical active microenvi-
ronment and interacts with the coronaries and the myocar-
dium.1,2 Therefore, the pericardial space is considered to
be a potential ideal site for local drug therapy for myocar-
dium and coronaries. Intrapericardial drug delivery has ad-
vantages over systemic administration: it provides higher
intramural concentrations, has fewer side effects that may
accompany systemic administration, is highly reproducible,
and has a high efficiency of localization.3,4 Furthermore,
drug delivery into a low-turnover reservoir may prevent
a rapid washout of agents.
Platelets contain storage pools of various growth factors
and cytokines.5 An increased understanding of the role of
platelets in wound healing led to the idea of using platelets
as ‘‘therapeutic vehicles.’’ In various tissues, platelets trap-
ped in a fibrin clot proved to serve as a site-specific slow-
release delivery system.6-8 Hypothetically, application of
platelet clots to ischemically injured myocardium might
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the stability of platelet clots when administered to the peri-
cardial sac. This study assessed the stability of 4 different
platelet clot compositions over time in pigs and in patients.
In vitro clots served as controls.
MATERIALS AND METHODS
Preparation and Application of Autologous Platelet
Gel and Platelet-Rich Fibrin Clots
Animal experiments were performed in accordance with the Guide for
the Care and Use of Laboratory Animals, as approved by the National Re-
search Council (National Institutes of Health), and were approved by the
committee on the care and use of experimental animals at our institute. Sim-
ilarly, clinical experiments were approved by the medical ethical committee
of our institution, and all patients provided informed consent.
Venous blood was freshly obtained from pigs and patients. To monitor
clot dynamics properly, autologous platelet gel (APG) and platelet-rich fi-
brin (PRF) clots were manufactured in vitro in a standardized way: platelet
clots with 2.7-cm diameter and approximately 1-cm height were manufac-
tured in plastic sterile sample cups. Before application to the pericardial
sac, initial clot weight was measured (Figure 1).
The Magellan Autologous Platelet Separator System and Disposables
Kit (Medtronic Inc, Minneapolis, MN) were used to manufacture platelet-
rich plasma (PRP) and thrombin. A detailed description of the PRP prepa-
ration method is available at the manufacturer and can be found elsewhere.10
In short, 52 mL of whole blood was drawn into a 60-mL syringe, preaspired
with 8 mL of anticoagulant citrate dextrose (0.022 g/mL sodium citrate).
The syringe was processed to yield 8 mL of PRP, 3 mL of which was
used to generate 2.5 mL of thrombin. Thrombin activator reagents include
glass fiber and calcium chloride 10%. The final thrombin activity approxi-
mated 10 to 15 IU/mL.11 The factor of increase in platelet concentration
over baseline whole blood level depends on the chosen volume PRP to be
produced. According to the manufacturer, in our study the plateletrgery c May 2009




APG ¼ autologous platelet gel
BU ¼ batroxobin units
PRF ¼ platelet-rich fibrin
PRP ¼ platelet-rich plasma
concentration would approximate 6 times the baseline whole blood level
(minimum platelet count 1000 3 103/mm3). Regardless of chosen PRP
amount, PRP fibrin(ogen) content remains at whole blood level (averaging
2.3 mg/mL). Subsequently, the platelet concentrate was mixed with throm-
bin. This induced activation of platelets and resulted in the formation of an
APG. Two fibrinolysis inhibitors, aprotinin and tranexamic acid, were tested
for their capacity to stabilize APG. Aprotinin acts as a reversible, competi-
tive inhibitor of plasmin. Tranexamic acid inhibits plasminogen activation
by preventing binding of plasminogen to fibrin. Before platelet activation,
either 30 mg/mL tranexamic acid (Cyklokapron; Pharmacia and Upjohn
AB, Stockholm, Sweden) or 3000 kIU/mL aprotinin (Trasylol; Bayer,
Leverkusen, Germany) were mixed with PRP.
The Vivostat Processor Unit (Vivolution A/S, Birkeroed, Denmark) and
the Vivostat PRF Preparation Kit were used to prepare PRF. PRF is an au-
tologously derived tissue sealant in which platelets get trapped. A detailed
description of the production process is available at Vivolution A/S and can
be found elsewhere.12 In short, 120 mL of whole blood was drawn into the
collecting unit, which was preaspired with acid-citrate solution containing
tranexamic acid (100 mg) and centrifuged. Subsequently, the PRP was con-
verted into an acid-soluble fibrin I polymer by the addition of batroxobin (30
batroxobin units [BU] in the device, of which 6 to 9 BU remain in the PRF
after processing). The snake venom Batroxobin catalyzes the release of
fibrinopeptide A from fibrinogen without activating coagulation factor
XIII. The fibrin I polymer and the platelets were isolated by centrifugation
and dissolved in 0.2 mol/L acetate buffer (pH 4). About 6 mL of Vivostat
PRF comprising cross-linked fibrin II polymer enriched with the platelets
was obtained through neutralization of 7 parts of the acidic fibrin I solution
with 1 part of a 0.75 mol/L carbonate/bicarbonate buffer (pH 10). Polymer-
ization is mediated by activation of endogenous prothrombin to thrombin
that activates endogenous factor XIII. According to the manufacturer, the
platelet concentration would approximate 10 times to baseline whole blood
level (minimum platelet count 12003 103/mm3), whereas fibrin concentra-
tion averages 14 mg/mL.
In Vitro Model
Parallel to each porcine experiment, in vitro clots (ie, APG, APG plus
tranexamic acid, APG plus aprotinin, and PRF) were manufactured. All
clots were placed in closed, plastic test tubes and incubated in a stove at
37C for 48 hours.
Animal Model
Five Yorkshire-Landrace pigs (weight ranged from 60 to 75 kg) were se-
dated (ketamine 10 mg/kg intramuscularly, midazolam 0.5 mg/kg intramus-
cularly, and atropine 0.04 mg/kg intramuscularly), anesthetized (thiopental
sodium, 5 mg/kg intravenously), intubated, and mechanically ventilated
(mixture of oxygen and air 1:1). Anesthesia was maintained with midazolam
(1.0 mg $ kg1 $ h1 intravenously), sufentanyl citrate (4 mg $ kg1 $ h1 in-
travenously), and pancuronium bromide (0.1 mg $ kg1 $ h1 intravenously).
Euthanasia was obtained with pentobarbital sodium (20 mg/kg intrave-
nously). Electrocardiography was used to monitor heart rate, rhythm, and
ST-segment changes during the surgical procedures. Peak and mean arterial
and central venous pressures, end-expiratory CO2, pulse oxymetry, blood
gases (ie, pH, pCO2) were monitored during surgery. The pigs were kept
warm by an external heating mattress to maintain a rectal temperature ofThe Journal of Thoracic and C38C to 39C. Sodium-chloride solution, 0.2 to 0.35 mL $ kg1 $ min1,
was given intravenously. All pigs underwent a median sternotomy. After
making a 4- to 5-cm-long incision in the pericardium, freshly manufactured
clots were left behind in the lowest part of the pericardial sac. The pericardial
incision was approximated with suture wires during incubation. The clot res-
idue was taken out after 30 minutes and clot weight was measured. Each an-
imal consecutively received APG, APG plus tranexamic acid, APG plus
aprotinin, and PRF. After removal of the clot residue, clot weight was mea-
sured. All pericardial fluid was removed and the pericardial sac was rinsed
with saline. Redundant saline was removed and a washout period of 1
hour was applied before administering a new platelet clot.
Patient Model
To test whether results obtained from animal studies can be extrapolated
to humans, 10 patients (6 men; median age 74, range 61 to 81) undergoing
elective left internal thoracic artery–to–left anterior descending coronary ar-
tery bypass grafting, were included in this study. Five patients received an
APG clot and 5 patients, a PRF clot. Exclusion criteria included antiplatelet
therapy (unless stopped 10 days previous to surgery), anemia (hemoglobin
<13 g/dL in men and<12 g/dL in women), platelet count below 1503 103/
mm3, and fibrinolytic therapy (unless stopped 2 days previous to surgery).
In the operating room, venous blood was withdrawn and platelet clots were
manufactured. While harvesting the left internal thoracic artery, the platelet
clot was administered to the lowest part of the pericardial sac through a 4- to
5-cm-long incision. The pericardial incision was approximated with suture
wires during incubation. After 30 minutes, the clot was taken out. Before
and after incubation, clot weight was measured.
Statistical Analyses
The paired sample Wilcoxon rank-sum test was used to compare differ-
ences between initial and residual clot weight as well as differences between
various APG compositions and PRF. Unless stated otherwise, data are ex-
pressed as mean  standard deviation. Statistical analyses were carried
out using SPSS software, version 12.0 (SPSS Inc, Chicago, IL).
RESULTS
In vitro, APG, APG plus tranexamic acid, and APG plus
aprotinin liquefied almost completely within 60 minutes of
incubation, whereas PRF clots remained intact for (at least)
48 hours (Figure 2).
FIGURE 1. In vivo incubation of autologous platelet clot. Freshly manu-
factured autologous platelet gel clot in plastic test container just before ad-
ministration to the pericardial sac.ardiovascular Surgery c Volume 137, Number 5 1191
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not result in changes in heart rate and rhythm or ST-segments.
In addition, no changes in systolic and diastolic blood pres-
sure were recorded upon clot administration.
In pigs, after 30 minutes of intrapericardial incubation,
16.7%  7.8% (P< .05) of initial APG clot weight re-
mained (Table 1). Addition of tranexamic acid or aprotinin
to APG resulted in 19.5%  9.8% and 15.6%  8.6%
clot weight residue, respectively (both P< .05). Compared
with either APG formula, less clot weight reduction oc-
curred when PRF was administered to the pericardial sac
(ie, 66.4%  3.2% of initial clot weight remained; P<
.05). In 1 porcine PRF experiment, the incubation period
was extended to 4 hours. After the first 30 minutes, clot
weight was measured hourly. After 30 minutes, clot weight
was reduced to 61% of initial clot weight, and during the
consecutive 3.5 hours, clot weight was further reduced to
approximately 42% of initial clot weight.
In patients, after 30 minutes of incubation, 9.0% 1.5%
and 73.7%  2.6% (both P< .05) of initial APG and PRF
clot weight remained, respectively (Table 1).
DISCUSSION
The main findings of this study are: (1) in vitro, APG clots
of either composition liquefy almost completely within 60
minutes, although PRF clots remain intact for at least 48
hours; (2) application of platelet clots to the pericardial sac
does not impair cardiac function; (3) in pigs and in patients,
and irrespective of clot composition, APG is unstable; (4)
FIGURE 2. In vitro incubation of autologous platelet clots. After 60 min-
utes of incubation at 37C, the PRF clot remained solid while either APG
clot formula liquefied almost completely. APG, Autologous platelet gel;
APG-TXA, APG plus tranexamic acid; APG-AP, APG plus aprotinin;
PRF, platelet-rich fibrin.1192 The Journal of Thoracic and Cardiovascular SuPRF degrades significantly less compared with APG, both
in pigs and in patients.
In vitro experiments were designed to investigate exclu-
sively physical clot stability. Other potential causes of degra-
dation that take place in vivo, such as mechanical stress and
fibrinolysis, were thus precluded. All APG clots almost com-
pletely liquefied within a relatively short period of time. Clot
retraction (ie, the physiologic process of serum expression
out of a fibrin matrix due to the contractile properties of acti-
vated platelets) may be a plausible explanation of this obser-
vation. However, PRF did not show signs of clot retraction
within 48 hours of incubation. Batroxobin-induced fibrin po-
lymerization may account for this difference. In contrast to
thrombin (which is used to induce gelation in APG), batrox-
obin does not activate platelets that are trapped in the fibrin
network.13,14 Because clot retraction is a process exhibited
by activated platelets, a marked delay in clot retraction may
be expected upon batroxobin induced gelation.15
In pigs and patients, no adverse reactions upon application
of platelet clots to the pericardial sac were observed.
In both animals and patients, APG clot weight decreased
significantly to less than 20% and 10% of initial clot weight
after 30 minutes of incubation, respectively. Although the ex-
act cause of APG clot degradation in vivo is not completely
understood, there may be some other potential contributors to
platelet clot degradation besides the aforementioned clot
retraction. Because the mechanical strength of fibrin clots is
directly related to their fibrin concentration, low fibrin levels
in APG clots may have contributed to rapid degradation.
Buchta and colleagues16 and Christensen and associates10
performed in vitro analyses on the platelet-free Vivostat
formula and Magellan PRP, and they measured fibrin levels
approximating 15 mg/mL and 3 mg/mL, respectively. In-
deed, in our experience, PRF clots felt less ‘‘jelly’’ when
compared with APG clots. Thus, APG clots may be more vul-
nerable to mechanical stress in the pericardial sac, relative to
PRF clots. In addition, mesothelial cells lining the pericar-
dium are known for their capacity to secrete fibrinolytic fac-
tors into the pericardial sac.1,17,18 Thus, a high fibrinolytic
activity may have contributed to fibrin clot degradation as
well. Coadministration of antifibrinolytic drugs to APG did
not reduce the amount of fibrin clot degradation. Probably,
clot retraction as well as fibrin matrix weakness may have
prevented antifibrinolytics from showing their real potential
in slowing down fibrinolysis.TABLE 1. Pericardial platelet clot weight in pigs and patients
APG
(pig, n ¼ 5)
APG
(patient, n ¼ 5)
APGþ tranexamic acid
(pig, n ¼ 5)
APGþaprotinin
(pig, n ¼ 5)
PRF
(pig, n ¼ 5)
PRF
(patient, n ¼ 5)
Initial clot weight (g) 4.6  0.9 6.7  0.3 5.6  0.3 5.6  0.3 6.4  0.4 6.6  0.2
Residue clot weight (g) 0.8  0.5* 0.6  0.1* 1.1  0.5* 0.9  0.4* 4.3  0.4*y 4.8  0.2*z
Residue clot weight (%) 16.7  7.8 9.0  1.5 19.5  9.8 15.6  8.6 66.4  3.2 73.7  0.3
APG, Autologous platelet gel; PRF, platelet-rich fibrin. *Compared with initial clot weight (P<.05). yCompared with either porcine APG clot formula (P<.05). zCompared with
residue clot weight of clinical APG group (P< .05).rgery c May 2009
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or less similar extent. However, clot weight degradation was
significantly less than either APG clots. As discussed above,
due to their different manufacturing process, PRF clots are
less subject to clot retraction. In addition, PRF clots contain
a higher fibrin level and may therefore better cope with the
mechanical stress in the pericardial sac. However, in 1 ex-
tended observation time of 4 hours, PRF clots degraded to
about 42% of initial clot weight. Probably, a combination
of high pericardial fibrinolytic activity and intrapericardial
mechanical stress may have accounted for extensive platelet
clot degradation over time.
In addition to previously mentioned factors potentially
influencing platelet clot stability, there may be several
others. Differences in concentration of (non)activated coag-
ulation factors, platelet count and platelet (dys)function, for
example, due to high fibrin split product levels, may also
affect platelet clot stability.
Although the life span of APG and PRF clots in the peri-
cardial sac is rather limited, these and other fibrin-based
matrices proved to be effective site-specific slow-release de-
livery systems for drugs,19 growth factors,20 or stem cells21
within various surgical specialties (eg, oral-maxillofacial,
orthopedic, and general surgery)22 and within the treatment
of chronic skin and soft tissue ulcers.23 Slow-release deliv-
ery of growth factors in the pericardial sac may enhance neo-
vascularization of ischemically damaged myocardium.
Similarly, stem cells may be used to target cardiac repair.
Platelet clots loaded with antiarrhythmic agents, for exam-
ple, can be used to treat postoperative atrial fibrillation.
As discussed earlier, there may be several potential causes
of rapid fibrin matrix degradation. Quick degradation of
fibrin clots may implicate that coadministered therapeutics
will be released within a short period of time. For short-
term purposes, PRF may be a suitable carrier for drug deliv-
ery; however, a gradual and long-term release of therapeutics
in the pericardial sac may require a scaffold that better resists
these attacks. With recent developments in biotechnology
and bioengineering, several alternative biodegradable drug
delivery systems are becoming available.24,25
This study has several limitations. The intention of slow-
release drug delivery systems is to gradually release thera-
peutics over a certain time span. However, platelet clots
were exposed to the pericardial sac for a very short period
of time, which may probably not reflect their intended use
in clinical practice. Nevertheless, despite a limited incuba-
tion time in vivo, we were able to assess whether tested
platelet clots may be a suitable slow-release drug delivery
system for intrapericardial application.
We assumed a correlation between platelet clot weight re-
duction and the release of therapeutics. In some situations,
this may not hold true. If therapeutics are not trapped in or
bound to the fibrin network, they might diffuse out the clot.
Also, upon clot retraction, theoretically only serum mightThe Journal of Thoracic and Cbe expressed out of the fibrin matrix, leaving the therapeutics
inside. In this case, actual clot weight may decrease when
therapeutics are not released. To better study causes of plate-
let clot degradation or drug release, labeling of fibrinogen in
the platelet clot as well as labeling of the trapped therapeutic
might be an option. The former may enable assessment of the
exact causes of platelet clot degradation, and the latter may
help reveal whether intrapericardial platelet clot weight
reduction correlates to release of tested therapeutic.
Furthermore, the (fixed) sequence of applying different
platelet clots to the pericardial sac may have influenced re-
sults. Residual thrombin or batroxobin, or intrinsic activa-
tors, may have influenced the antifibrinolytic properties of
tested agents. By rinsing the pericardial sac thoroughly
with saline and applying a washout period of 1 hour, we em-
pirically aimed to minimize carryover effects. However,
whether a 1-hour washout period is sufficient to avoid carry-
over effects remains to be investigated.
Safety of intrapericardial platelet clot application should
be assessed more thoroughly before it can be clinically
adopted. Although platelet clots are relatively small and
mould easily in the pericardial sac, they might compress
(and thereby injure) epicardial tissue or affect graft patency.
The latter might also be affected due to potential hyperpro-
liferation at the anastomotic sites due to release of therapeu-
tics. Based on monitoring of heart rate and rhythm and
blood pressure, we assessed hemodynamic safety of intra-
pericardial platelet clot application. However, more sophis-
ticated techniques, such as echocardiography, may be used
to further evaluate effects of platelet clots on regional wall
motion.
In summary, this study investigated the stability of 4 dif-
ferent autologous platelet clot compositions when adminis-
tered to the pericardial sac, and in vitro clots served as
controls. APG in either composition is unstable both in vitro
and in vivo, whereas PRF remains intact in vitro for a longer
period of time and is less subject to degradation in animals
and patients.
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